Evidence map›Paper›PMID 24141203›Full record

ArticleEuropean journal of medicinal chemistry2013

Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.

Sidney Bolden, Xue Y Zhu, Jagan R Etukala, Comfort Boateng, Tryphon Mazu, Hernan Flores-Rozas, Melissa R Jacob, Shabana I Khan, Larry A Walker, Seth Y Ablordeppey

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. The Mechanistic Targets of Antifungal Agents: An Overview.Mini reviews in medicinal chemistry · 2016
    Review
  4. (E)-2-[4-(Di-ethyl-amino)-styr-yl]-1-methyl-quinolin-1-ium 4-chloro-benzene-sulfonate monohydrate.Acta crystallographica. Section E, Structure reports online · 2014
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sidney BoldenCollege of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
Xue Y Zhu
Jagan R Etukala
Comfort Boateng
Tryphon Mazu
Hernan Flores-Rozas
Melissa R Jacob
Shabana I Khan
Larry A Walker
Seth Y Ablordeppey

Funding

THE PREVENTION OF B(A)P INDUCED CELL TRANSFORMATION BY ORGANOSULFUR COMPOUNDSG12RR003020 · NCRR · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI SOLIMAN, KARAM F.A. · 1985 to 2011
$29.7M
Recruitment and HiringG12MD007582 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI SOLIMAN, KARAM F.A. · 2012 to 2017
$16.0M
Targeted Nanocarrier Combination Based Therapy for Lung CancerP20MD006738 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI SOLIMAN, KARAM F.A. · 2012 to 2016
$5.6M
NEW DRUGS FOR OPPORTUNISTIC INFECTIOUS DISEASESR01AI027094 · NIAID · UNIVERSITY OF MISSISSIPPI · PI CLARK, ALICE M. · 1989 to 2013
$4.4M
PHARMACEUTICAL RESEARCH CENTERC06RR012512 · NCRR · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI LEWIS, HENRY · 1997 to 1997
–
NCRR NIH HHS 1C06-RR12512-01NCRR NIH HHS C06 RR012512NCRR NIH HHS G12 RR003020NCRR NIH HHS G12 RR 03020NIAID NIH HHS AI 27094NIAID NIH HHS R01 AI027094NIMHD NIH HHS G12 MD007582NIMHD NIH HHS P20 MD006738
6 · The paper itself

Abstract

Opportunistic infections are devastating to immunocompromised patients. And in especially sub-Saharan Africa where the AIDS epidemic is still raging, the mortality rate was recently as high as 70%. The paucity of anti-opportunistic drugs, the decreasing efficacy and the development of resistance against the azoles and even amphotericin B have stimulated the search for new drugs with new mechanisms of action. In a previous work, we showed that a new chemotype derived from the natural product cryptolepine displayed selective toxicity against opportunistic pathogens with minimal cytotoxicity to normal cells. In this manuscript, we report the design and synthesis of substituted benzylthioquinolinium iodides, evaluated their anti-infective properties and formulated some initial structure-activity relationships around phenyl ring A from the original natural product. The sensitivity of the most potent analog 10l, to selected strains of C. cerevisiae was also evaluated leading to the observation that this scaffold may have a different mode of action from its predecessor, cryptolepine.

Indexed as

AnimalsAnti-Bacterial AgentsAntifungal AgentsBacteriaBiological ProductsChlorocebus aethiopsDose-Response Relationship, DrugDrug DesignFungiMicrobial Sensitivity TestsMolecular StructureQuinolinium CompoundsStructure-Activity RelationshipVero CellsAnti-Bacterial AgentsAntifungal AgentsBiological ProductsQuinolinium CompoundsAntifungal agentsAnti-opportunistic infectionsBenzylthioquinolinium iodidesCraig plotCryptolepineStructure–activity relationshipsSubstituted quinolinium salts

Identifiers

PMID24141203
PMCPMC3870201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.